Back to search

Massachusetts Institute of Technology

Impact of communications between firms on innovation and new product development : the case of the Cambridge/Boston biotech cluster

Abstract

dc:description.abstract

The paper reports the results of a study of innovations and new product development in biotechnology and pharmaceutical companies in Boston/Cambridge cluster. The purpose of the study was to test the hypothesis that more intensive or frequent communications correlate positively with higher productivity, measured as the number of patents, new drugs or clinical trials per employee. No significant correlations were found between communications and new drugs or clinical trials. Statistically significant (p < 0.05) negative correlations were found between Number of Patents per Employee and the three metrics devised for intensity of communications.

Degree

thesis:*
Department dc:contributor.department
Massachusetts Institute of Technology. Engineering Systems Division.
Grantor dc:publisher
Massachusetts Institute of Technology
Year dc:date.issued
2011

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Kolosov, Dmitry, S.M. Massachusetts Institute of Technology
Advisor dc:contributor.advisor
  • Thomas J. Allen.

Subjects

dc:subject × 2

Rights

dc:rights
Statement dc:rights
  • M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission.
Language dc:language.iso
eng

Identifiers

dc:identifier.*
Handle dc:identifier.uri
http://hdl.handle.net/1721.1/67558
OAI identifier oai:identifier
oai:dspace.mit.edu:1721.1/67558

Chain of custody

source
Harvested from
MIT
Base URL
dspace.mit.edu/oai/request
Last updated
2026-07-22
Source record
OAI-PMH GetRecord
citation

Kolosov, Dmitry, S.M. Massachusetts Institute of Technology. Impact of communications between firms on innovation and new product development : the case of the Cambridge/Boston biotech cluster. Massachusetts Institute of Technology, 2011. http://hdl.handle.net/1721.1/67558